Clear Creek Financial Management LLC Acquires 51,390 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA)

Clear Creek Financial Management LLC Acquires 51,390 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA)

Clear Creek Financial Management LLC raised its holdings in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) by 323.6{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,270 shares of the company’s stock after purchasing an additional 51,390 shares during the quarter. Clear Creek Financial Management LLC owned 0.17{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of Cassava Sciences worth $1,987,000 as of its most recent filing with the Securities & Exchange Commission.

→ The “King Of Quants” sees 10X potential… (From Investor Place Media)

Several other institutional investors have also bought and sold shares of the business. IVC Wealth Advisors LLC raised its stake in shares of Cassava Sciences by 2.8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the third quarter. IVC Wealth Advisors LLC now owns 14,815 shares of the company’s stock valued at $620,000 after acquiring an additional 400 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Cassava Sciences by 28.6{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the second quarter. Virtus ETF Advisers LLC now owns 4,241 shares of the company’s stock valued at $119,000 after acquiring an additional 942 shares during the period. SOA Wealth Advisors LLC. raised its stake in shares of Cassava Sciences by 679.5{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the third quarter. SOA Wealth Advisors LLC. now owns 608 shares of the company’s stock valued at $25,000 after acquiring an additional 530 shares during the period. Valeo Financial Advisors LLC purchased a new stake in shares of Cassava Sciences in the third quarter valued at $205,000. Finally, Cambridge Investment Research Advisors Inc. raised its stake in shares of Cassava Sciences by 5.8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the third quarter. Cambridge Investment Research Advisors Inc. now owns 14,608 shares of the company’s stock valued at $611,000 after acquiring an additional 806 shares during the period. Institutional investors own 25.51{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the company’s stock.

Insider Buying and Selling

In related news, Director Richard Barry purchased 11,565 shares of Cassava Sciences stock in a transaction that occurred on Monday, March 6th. The shares were bought at an average price of $26.13 per share, with a total value of $302,193.45. Following the purchase, the director now directly owns 197,724 shares of the company’s stock, valued at approximately $5,166,528.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.10{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the stock is currently owned by insiders.

Cassava Sciences Trading Up 0.7 {21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}

SAVA stock traded up $0.16 during trading on Friday, hitting $24.17. The company had a trading volume of 353,874 shares, compared to its average volume of 1,248,024. Cassava Sciences, Inc. has a 52-week low of $13.84 and a 52-week high of $51.59. The company has a 50 day simple moving average of $26.79 and a 200-day simple moving average of $32.59.

Cassava Sciences (NASDAQ:SAVA – Get Rating) last posted its quarterly earnings results on Tuesday, February 28th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.11. On average, research analysts anticipate that Cassava Sciences, Inc. will post -0.76 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SAVA. HC Wainwright reissued a “buy” rating and issued a $124.00 target price on shares of Cassava Sciences in a research note on Monday, March 6th. B. Riley reduced their target price on shares of Cassava Sciences from $44.00 to $28.00 in a research note on Wednesday, January 25th.

Cassava Sciences Company Profile

(Get Rating)

Cassava Sciences, Inc engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Read More

Want to see what other hedge funds are holding SAVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating).

Institutional Ownership by Quarter for Cassava Sciences (NASDAQ:SAVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Cassava Sciences, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Cassava Sciences wasn’t on the list.

While Cassava Sciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2023 Cover

Financial Analysts Share Views on ATAI Life Sciences Stock

Financial Analysts Share Views on ATAI Life Sciences Stock

Six money analysts have a short while ago shared their sights on the efficiency of ATAI Lifestyle Sciences (NASDAQ: ATAI) stock. Centered on their ratings, the consensus is a Average Get, with a single analyst keeping and five recommending a Invest in. The common 12-thirty day period price prediction for ATAI Existence Sciences is $14.29, with a superior goal of $27.00 and a small target of $9.00.

Five analysts have furnished their 12-thirty day period rate targets for ATAI Everyday living Sciences in the previous a few months. The Wall Street Journal described that a single analyst rated the inventory as a Buy 3 months back, and an additional rated it as a Invest in a single month in the past. The company’s common price target is $30.6, with a superior of $40.00 and a very low of $27.00.

It is vital to don’t forget that these scores and rate targets are matter to change based mostly on things such as marketplace ailments and enterprise performance. Hence, investors need to carry out their analysis and evaluation prior to creating expenditure choices.

ATAI Existence Sciences: A Blended Overall performance in the Stock Marketplace with Optimistic Upcoming Projections

ATAI Everyday living Sciences, a leading biotech organization in the Overall health Technological innovation sector, has experienced a mixed efficiency in the stock marketplace around the previous yr. The company’s past shut was 1.25, and today’s opening a little bit increased to 1.29. Nonetheless, the day’s variety has been risky, with price ranges ranging from 1.27 to 1.38. The quantity traded nowadays has been 26,155, considerably lower than the average quantity of the earlier three months, which stands at 1,321,425.

ATAI’s industry capitalization is $207.3M, which is fairly lower for a pharmaceutical organization. The company’s earnings advancement past calendar year was positive, with a advancement level of 6.30{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. On the other hand, this year’s earnings growth has been detrimental, with a decrease of 2.30{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. In spite of this, analysts are optimistic about the company’s long term, with an predicted earnings growth fee of 22.20{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} above the next five years.

ATAI’s profits growth final yr was destructive, with a drop of 98.86{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. This is a stressing craze for traders, as profits is a very important indicator of a company’s money wellbeing. Nevertheless, it is crucial to be aware that the company is continue to in its early stages, and profits progress is predicted to increase in the coming a long time.

The company’s P/E ratio is unavailable, which indicates that the organization is not however rewarding. The rate/sales ratio is 1,777.74, substantially bigger than the sector ordinary. This signifies that the company’s inventory may be overvalued.

ATAI has no competitor data, producing comparing the company’s functionality with its friends complicated. The company’s upcoming reporting date is May possibly 15, 2023, which will offer buyers with a lot more data about the company’s financial efficiency.

The EPS forecast for this quarter is -$.22, which suggests that the firm is expected to report a decline. The yearly profits for previous calendar year was $233.0K, which is a relatively little total for a pharmaceutical company. The company’s internet income margin is -65,401.29{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}, which indicates that the enterprise is not nonetheless rewarding.

In conclusion, ATAI Existence Sciences has had a combined general performance in the stock market place around the earlier yr. Though the company’s earnings expansion previous year was positive, this year’s advancement has been detrimental. The company’s income expansion has also been adverse, a stressing pattern for investors. Having said that, analysts are optimistic about the company’s long term, with an predicted earnings progress rate of 22.20{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} over the subsequent 5 a long time. Traders ought to keep track of the company’s financial general performance in the coming yrs to make educated financial investment conclusions.

ATAI Everyday living Sciences NV: A Biotech Firm Centered on Psychological Health Ailments Creating Waves in the Stock Industry

ATAI Lifetime Sciences NV, a biotech company centered on producing remedies for mental health and fitness diseases, has been producing waves in the inventory sector these days. In the previous few months, the company’s inventory general performance has been the subject matter of a great deal dialogue among the buyers and analysts alike.

In accordance to info from CNN Money, the 12 analysts presenting 12-month rate forecasts for ATAI have a median focus on of $11.00, with a large estimate of $21.00 and a small estimate of $5.10. This signifies a staggering +714.81{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} increase from the company’s last price of $1.35.

The consensus among the 14 polled expense analysts is to invest in stock in ATAI Lifetime Sciences NV. This ranking has held regular considering that January, when it was unchanged from a buy rating.

In spite of the company’s current achievement in the inventory marketplace, ATAI has but to revenue. In the recent quarter, ATAI documented earnings for every share of -$.22 and sales of $.00. The corporation is established to report its subsequent earnings on May well 15.

So what is driving ATAI’s inventory effectiveness? The company’s emphasis on establishing treatment options for mental wellbeing problems is unquestionably a variable. Psychological wellbeing has turn out to be an ever more critical difficulty in new several years, and a lot of investors see potential in corporations that are functioning to address this challenge.

In addition, ATAI has been producing strategic acquisitions and partnerships to increase its portfolio of treatment options. In March, the business acquired a majority stake in Recognify Daily life Sciences, a biotech firm targeted on establishing treatments for stress and melancholy. This acquisition is expected to strengthen ATAI’s position in the mental wellbeing market.

All round, ATAI’s stock efficiency has been extraordinary in modern months. Whilst the firm has still to earnings, its concentration on producing treatment options for mental well being disorders and strategic acquisitions and partnerships have produced it an eye-catching investment decision opportunity for lots of traders. As the enterprise carries on to increase and produce new solutions, it will be intriguing to see how its stock general performance evolves.